Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin
DC CAFC
First Claim
Patent Images
1. An IL-2 transcription inhibitor and 40-O-(2-hydroxyethyl)-rapamycin as a combined pharamceutical preparation in the weight ratio 2:
- 1 to 180;
1 for simultaneous, separate, or sequential use in synergistically effective amounts.
0 Assignments
Litigations
1 Petition
Accused Products
Abstract
A synergistic combination of an IL-2 transcription inhibitor (e.g., cyclosporin A or FK506) and 40-O-(2-hydroxyethyl)-rapamycin is provided, which is useful in the treatment and prevention of transplant rejection and also certain autoimmune and inflammatory diseases, together with novel pharmaceutical compositions comprising an IL-2 transcription inhibitor in combination with a rapamycin, e.g., 40-O-(2-hydroxyethyl)-rapamycin.
71 Citations
20 Claims
-
1. An IL-2 transcription inhibitor and 40-O-(2-hydroxyethyl)-rapamycin as a combined pharamceutical preparation in the weight ratio 2:
- 1 to 180;
1 for simultaneous, separate, or sequential use in synergistically effective amounts.
- 1 to 180;
-
2. A pharmaceutical composition comprising (I) an IL-2 transcription inhibitor and (II) 40-O-(2-hydroxyethyl)-rapamycin, wherein the weight ratio II is 2:
- 1 to 180;
1, in combination or association with a pharmaceutically acceptable diluent or carrier. - View Dependent Claims (3, 4, 5, 6)
- 1 to 180;
-
7. A method of treating or preventing an autoimmune or inflammatory condition or transplant rejection in a subject suffering from or at risk for such condition or rejection, comprising co-administering synergistically effective amounts of (I) an IL-2 transcription inhibitor and (II) 40-O-(2-hydroxyethyl)-rapamycin in the weight ratio 2:
- 1 to 180;
1. - View Dependent Claims (8, 9, 10)
- 1 to 180;
- 11. A method of treating or preventing chronic rejection of a heart, lung, or kidney transplant in a subject suffering from or at risk for such rejection, comprising co-administering together or at substantially the same time synergistically effective amounts of (I) an IL-2 transcription inhibitor and (II) 40-O-(2-hydroxyethyl)-rapamycin.
-
18. A kit comprising (I) an IL-2 transcription inhibitor and (II) 40-O-(2-hydroxyethyl)-rapamycin in separate unit dosage forms, wherein said unit dosage forms are suitable for administrating I and II in synergistically effective amounts, wherein the weight ratio II is 2:
- 1 to 180;
1. - View Dependent Claims (19, 20)
- 1 to 180;
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
Litigation Data
-
Current AssigneeNovartis Ag
-
Original AssigneeNovartis Ag
-
InventorsSchuurman, Hendrik, Zenke, Gerhard, Meinzer, Armin, Haeberlin, Barbara
-
Primary Examiner(s)Weddington, Kevin E.
-
Application NumberUS09/758,301Publication NumberTime in Patent Office621 DaysField of Search514/183, 514/514, 514/516, 514/31US Class Current514/183CPC Class CodesA61K 2300/00 Mixtures or combinations of...A61K 31/445 Non condensed piperidines, ...A61K 31/45 having oxo groups directly ...A61K 31/70 Carbohydrates; Sugars; Deri...A61K 38/13 CyclosporinsA61K 45/06 Mixtures of active ingredie...A61K 9/146 with organic macromolecular...A61K 9/4858 Organic compoundsA61P 17/14 for baldness or alopeciaA61P 29/00 Non-central analgesic, anti...A61P 37/00 Drugs for immunological or ...A61P 37/02 ImmunomodulatorsA61P 37/06 Immunosuppressants, e.g. dr...A61P 37/08 Antiallergic agents antiast...A61P 43/00 Drugs for specific purposes...
